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As funding available to health services is limited, demonstrating the cost effectiveness of new technologies is an important step in their
introduction. This is especially challenging for diagnostic technologies, for which the usual paradigm of reliance on well-designed,
randomised controlled trials may not be appropriate. A recently completed Health Technology Assessment of fluorine-18
deoxyglucose (FDG)-positron emission tomography (PET) imaging in cancer management, focused on addressing whether the
introduction of PET imaging would be beneficial to patients in the NHS in Scotland, exemplifies some of the challenges. Although a
substantial body of published literature exists for this technology, most of the studies report diagnostic accuracy rather than improved
patient outcomes. Direct evidence that such improvement occurs, and is sufficient to meet the NHS’ criteria for cost effectiveness,
from well-designed trials would constitute the most immediately persuasive case for the introduction of PET imaging. In the absence
of such evidence, collaboration is required between a variety of disciplines to synthesise evidence from a variety of sources to create
informative decision models that estimate long-term patient outcomes. The use of such decision models enabled the Health
Technology Board for Scotland (now a part of NHS Quality Improvement Scotland) to determine that FDG-PET imaging is likely to
be cost effective in selected applications and identified long-term patient benefits that it would not be possible to study in a
randomised controlled trial.
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Any health technology that is new or not readily available is likely
to generate pressure for immediate implementation by clinical
enthusiasts. When, as is the case with positron emission
tomography (PET) imaging, the UK is perceived as ‘lagging
behind’, the pressure for investment is likely to be particularly
intense. However, in any health-care system with limited
resources, priorities for investment must be set on the basis of
clear evidence of benefit to patients and good value for the money
spent.
PET imaging using fluorine-18 deoxyglucose (FDG) has, since
its introduction, offered oncologists the possibility of gaining
insights into the biochemical activity of tumours in addition to
examining the anatomical structure (Phelps, 2000). These insights
may be valuable in staging disease, restaging disease after the
completion of therapy or detecting tumour response early during
therapy.
However, many exciting and potentially valuable therapies
compete for funding available to health services – simply
introducing all of them is impossible. This has encouraged the
development of the Health Technology Assessment (HTA)
discipline, and the establishment of the National Institute for
Clinical Excellence and the Health Technology Board for Scotland
(HTBS) – now part of NHS Quality Improvement Scotland. Each
organisation advises the NHS in England and Wales, and
NHSScotland, respectively, on whether or not new and existing
technologies and therapies appear to offer ‘good value’. Although
not all the recommendations of these organisations have been
universally acclaimed (Saunders and Valle, 2002), there is
considerable support for the idea that some such assessment is
needed. But what might constitute evidence of good value for a
diagnostic technique such as PET?
In October 2002, HTBS launched its assessment of PET imaging
in cancer management (Bradbury et al, 2002) – the 13th
assessment of PET published since 1990. Why such apparent
continuing controversy about a diagnostic technique that was first
described in 1958 (Anger, 1958) and whose application in cancer is
the subject of over 1800 published articles? Is this, as Ell (2002)
suggests, because ‘well-meaning’ people set barriers that are
effectively insurmountable, or because there is a genuine mismatch
between what is published and what is needed to demonstrate that
PET imaging is ‘good value’ for the tax or insurance payer’s penny?
These questions can be answered by considering the issues that
confronted our own HTA. These issues are relevant not only to
PET imaging but also to similar emerging diagnostic technologies,
such as microarray genetic assays of cancer (Alizadeh et al, 2000;
Bittner et al, 2000).
The fundamental concept of HTA is that one needs to find
evidence that the use of PET imaging can improve the length or
quality of patients’ lives at reasonable cost, or that it can reduce the
overall expenditure without substantially reducing the effective-
ness of patient care, that is the ‘higher order’ outcomes in the
hierarchy of forms of evidence described by Fryback and
Thornbury (1991). Unfortunately, most research published to date
has focused on the diagnostic accuracy of PET, with little attention
paid to demonstrating the consequences (if any) of improved
accuracy for long-term patient outcomes (Lassen, 2001). This has
led to the current and rather frustrating situation of enthusiasts
declaring that PET imaging is now essential, for example, in
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(Medicare, 2001; Reske et al, 1996), while a succession of HTA
agencies declare that PET staging is ‘interesting’, and that it may be
clinically effective but more research is needed (Lassen, 2001;
Medical Services Advisory Committee, 2001).
Following the same successful paradigm as in drug applications,
HTA agencies tend to call for more prospective randomised
studies, in which PET imaging is considered as an alternative or
supplement to conventional diagnostic procedures. Patients are
treated on the basis of these results following an agreed protocol,
and outcomes such as survival, quality of life and cost are
recorded. This is all very straightforward, so why have not lots of
these studies been undertaken? Indeed, why has only one trial
approximating to this recipe for PET been published to date (van
Tinteren et al, 2002)?
We believe that there are a number of factors responsible for
this. Firstly, although such trials would provide ideal evidence of
long-term patient benefit, they would be inefficient and possibly
unhelpful in assessing the diagnostic accuracy (in a new
indication) or utility (when accuracy has already been shown) of
PET imaging. This is because the effect of imaging would be
confounded with the effects of therapy. Indeed, in many cases,
such an approach might be seen as ‘using a poor therapy to judge a
good diagnostic method’. Secondly, such trials rely on investiga-
tors closely following a protocol that specifies the order in which
tests are done, and how the test results will be used to determine
treatment. This may happen more rarely than one might wish. For
example, one major difficulty in assessing the utility of PET
imaging for NHSScotland has been the lack of agreement between
oncologists as to how it may best be used. However, the
introduction of Managed Clinical Networks is likely to improve
this situation (Scottish Executive Health Department, 2001).
Other problems in undertaking trials include:
 the lack of incentive for support from manufacturers, since
device authorisation is based mainly on safety rather than
efficacy;
 the belief that the case for PET imaging is already proven;
 the lack of incentive for major US centres to undertake such
studies, since reimbursement is already available on the basis of
accuracy data and some evidence of cost savings (in the high-
cost US environment);
 the daunting timescales required for many potentially important
studies. For example, studies of delayed or avoided radiotherapy
in non-Hodgkin’s lymphoma could require a follow-up of 20
years to detect potential second tumours;
 the wide variety of radiotracers potentially available for PET
imaging in oncology.
NSCLC – RANDOMISED CONTROLLED TRIALS
The one application, in which a randomised controlled trial (RCT)
has been published involves testing PET in addition to current
staging vs current methods alone to evaluate NSCLC patients for
surgery (van Tinteren et al, 2002). This study reported that PET
imaging allowed futile (i.e., demonstrably noncurative) thoraco-
tomies to be avoided and was cost saving in the Dutch health-care
service. Unfortunately, although it appears reasonable that the
avoidance of such surgery may improve the quality of patients’
lives, this study did not collect the evidence needed to support this.
Since there is no evidence that avoiding unnecessary surgery
significantly improves survival, the justification for PET in this
case depends ultimately on costs. Since costs may be different in
the UK from those in the Netherlands, it is entirely possible that
the same study could justify a different decision here, specifically if
surgery is substantially cheaper in the UK than in the Netherlands.
Adding to the possibilities for confusion is an Australian RCT,
published only as an American Society of Clinical Oncology
presentation (Boyer et al, 2001), which resulted in no evidence for
any difference in futile thoracotomies between the two groups. It
appears that some of the discrepancies between these studies are
caused by different approaches to treating patients with computed
tomography (CT)-positive PET-negative disease in the mediasti-
num. The Dutch investigators regarded all patients with this stage
of disease as inoperable, whereas the Australians would often still
operate. Unfortunately, it seems that the trials do not offer
definitive conclusions, and that assessment is dependent on
decision models.
NSCLC – MODELLING
Briefly, a decision model attempts to reflect local surgical decision-
making, cost structures and the impacts of both treatment and
disease on quality of life, and to link the increased accuracy of PET
to final outcomes through a decision-tree approach (Dietlein et al,
2000). The overall expected benefit from a number of alternative
actions may then be compared, and that yielding the highest
expected benefit selected as the most cost-effective strategy.
A number of such models of varying sophistication have been
published for NSCLC (Gambhir et al, 1996; Scott et al, 1998;
Dietlein et al, 2000). We chose to base our assessment of PET in
early stage NSCLC on the Dietlein et al study, and amended it to
take account of recently published accuracy data, costs within
NHSScotland and local clinical opinion on how PET imaging
would most likely be used. The conclusions from this model are
detailed in the published report (Bradbury et al, 2002). In
summary, the model indicated that PET imaging appears to be
cost effective only in patients with no evidence of abnormal lymph
nodes on CT scan. All such patients who also appear normal on
PET scan should be operated upon. Apparent abnormalities on
PET scan should also be confirmed by mediastinoscopy-guided
biopsy before denying a patient an operation.
However, the simple single-variable sensitivity analyses we
performed suggest that the model conclusions are extremely
sensitive to a number of uncertain values, on which more
information is required, specifically:
 the quality and length of survival after surgical or nonsurgical
treatment for patients with N2 disease;
 the appropriate quality of life ‘penalty’ associated with a
thoracotomy (in particular, whether a larger penalty is
appropriate for futile thoracotomies);
 the accuracy of mediastinoscopy-guided biopsy;
 the accuracy of PET imaging in detecting distant metastases;
 the actual cost of surgery to NHSScotland.
Note that the accuracy of PET imaging for detecting NSCLC is
not part of this list, and that the value of further studies of
accuracy in staging mediastinal disease in NSCLC is likely to be
minimal, although well-designed studies to assess accuracy in
detecting distant metastases should be welcomed. To obtain the
required information, a randomised trial of PET imaging is not
necessarily the only appropriate tool. Many of the data needed may
be collected more efficiently from audits of routine practice, or by
appropriately designed surveys.
GUIDING STUDY DESIGN
So, we have moved on somewhat from the blanket approach ‘do
more research, do another RCT’, but is it possible to be more
precise and to describe how much further research might be
needed? The answer is ‘yes’, but with considerable caution, using
the emerging tools of probabilistic sensitivity analysis and value of
information analysis (Fenwick et al, 2000; Laking et al, 2002a).
Such methods, developed within the Bayesian decision theory
(Berry, 1995), allow one to estimate the value of further
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the uncertainty about a possible decision. These methods have
been applied successfully in a number of areas to include
engineering fields such as hydrology (Reichard and Evans, 1989)
and radiation safety (French and Smith, 1997), and in investment
appraisal (J Craig, personal communication, February 2003) and
have recently been suggested as useful alternatives to the simple
statement ‘more research is needed’ (Claxton and Posnett, 1996;
Phillips, 2001; Laking et al, 2002b).
In outline, the methods are a simple extension of decision
modelling. Since our knowledge of the effects of the actions
modelled is unlikely to be perfect, there will remain uncertainty.
Essentially, the magnitude of this uncertainty will determine how
much effort or money should be expended to reduce it.
Of course, if it were all so simple, we would have been doing it
for a long time. Setting aside the nontrivial technical challenges,
the main barrier to these methods is that to provide sensible
answers, one has to take account of all the currently available
information. Although this may be relatively straightforward for
some therapies in which a large body of ‘high-quality’ randomised
trial evidence is available, the implications in areas such as
diagnostic testing, where trial quality is more variable, and for
epidemiological inputs, such as disease prevalence, are substantial
and not fully worked out as yet (see, for example, Ades and Cliffe,
2002). Certainly, it will no longer be enough simply to summarise
the RCTs, and discard the rest.
HODGKIN’S DISEASE – MODELLING
As an illustration of this approach, we attempted to assess the net
benefit based on a complex (37-state) model of using PET imaging
in patients with ‘bulky’ Hodgkin’s disease after initial ABVD
(doxorubicin, bleomycin, vinblastine and dacarbazine) chemother-
apy to determine whether or not the patient should receive
immediate consolidative radiotherapy. The model incorporated
evidence from all available published studies, both on PET and CT
accuracy and on the long-term prognosis of Hodgkin’s disease. We
compared a ‘current practice’ model of basing the decision on the
presence of abnormalities on CT scan to two alternatives, one in
which PET imaging was used only in patients with residual CT
abnormalities and a second in which PET imaging was used in all
the patients regardless of the CT results. It is instructive to
consider the wide variety of inputs needed, even for such a
relatively simple decision problem.
As the possible adverse effects of radiotherapy are likely to
manifest after a number of years (Hancock et al, 1993), the model
needed to account for the effects not only of initial therapy, but
also of potential salvage and palliative therapies. We are grateful to
clinical colleagues for advice on the possible pathways for such
patients. However, in addition to such ‘structural’ information, the
model required the maximum information possible on:
 sensitivity and specificity of PET and CT;
 relapse rates after ABVD therapy, with and without consolida-
tion;
 response rates to salvage therapy;
 the toxicity of salvage therapy;
 survival rates after response to salvage therapy;
 the long-term toxicity of radiotherapy;
 cost data for all the possible therapies.
It is clear that such modelling exercises will not be undertaken
lightly and will rely heavily on expert opinion, both to select and to
supplement the available data sources. Inevitably, such modelling
will be criticised for its possible subjectivity, and will only be
plausible if performed within a disciplined framework akin to that
provided to the pharmaceutical industry by the International
Conference on Harmonization (ICH) guidance (http://www.ifp-
ma.org/ich5e.html) (Facey and Lewis, 1998).
However, we believe that only such complete and necessarily
complex modelling exercises will be able to provide both evidence
for the cost effectiveness of diagnostic technologies such as PET
imaging and appropriate guidance for further research.
For Hodgkin’s disease, the modelling results led HTBS to
recommend that PET scanning should be used in clinical practice
to restage patients after ABVD therapy. In contrast to the
implausible 20 years that may be required for a definitive RCT,
the modelling exercise occupied 6 months. We recognise, however,
the need for more experience on the use of this PET technology in
practice, and a key recommendation of the HTA is that treatment
and outcome data should be collected on all patients undergoing
PET imaging.
Interestingly, our model predicts that using PET scanning
results to determine therapy in all patients will be more effective
than using PET imaging only in CT-positive patients, essentially
because the sensitivity of the combined procedure is lower than
that of PET or CT imaging alone. We recognise, however, that the
policy of imaging only the CT-positive patients is a less dramatic
change from current practice, and may therefore be preferred.
CONCLUSION
The HTA has covered only two of the possible therapeutic areas for
FDG-PET imaging in oncology. The process of relating accuracy
data to outcomes through careful detailed modelling exercises
needs to be extended to other cancers, perhaps most obviously and
immediately non-Hodgkin’s lymphoma, recurrent head and neck
cancer, malignant melanoma and solitary pulmonary nodules. As
well as helping to build the evidence base for PET imaging, such
large-scale collaboration between economists, statisticians, clin-
icians and physicists would provide valuable insights into how the
process of economic modelling might best be formalised and
regulated in HTA. Within NHSScotland, the conclusion of our
assessment is best phrased in terms of the classification suggested
by Claxton et al (2002)– ‘implement, but research further’.
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